243 related articles for article (PubMed ID: 37736550)
1. ExoPD-L1: an assistant for tumor progression and potential diagnostic marker.
Hu R; Jahan MS; Tang L
Front Oncol; 2023; 13():1194180. PubMed ID: 37736550
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer.
Park SJ; Park JY; Shin K; Hong TH; Lee M; Kim Y; Kim IH
BMC Cancer; 2023 May; 23(1):389. PubMed ID: 37127565
[TBL] [Abstract][Full Text] [Related]
3. Exosomal PD-L1 in cancer and other fields: recent advances and perspectives.
Lu MM; Yang Y
Front Immunol; 2024; 15():1395332. PubMed ID: 38726017
[TBL] [Abstract][Full Text] [Related]
4. Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies.
Zhou K; Guo S; Li F; Sun Q; Liang G
Front Cell Dev Biol; 2020; 8():569219. PubMed ID: 33178688
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy.
Shin K; Kim J; Park SJ; Lee MA; Park JM; Choi MG; Kang D; Song KY; Lee HH; Seo HS; Lee SH; Kim B; Kim O; Park J; Kang N; Kim IH
Sci Rep; 2023 Apr; 13(1):6952. PubMed ID: 37117200
[TBL] [Abstract][Full Text] [Related]
6. Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection.
Chen X; Du Z; Huang M; Wang D; Fong WP; Liang J; Fan L; Wang Y; Yang H; Chen Z; Hu M; Xu R; Li Y
Cancer Immunol Immunother; 2022 Mar; 71(3):661-674. PubMed ID: 34322779
[TBL] [Abstract][Full Text] [Related]
7. Coaxial dual-path electrochemical biosensing and logic strategy-based detection of lung cancer-derived exosomal PD-L1.
Liu J; Liu Z; Zhao C; Jiao Y; Li B; Shi J; Chen Z; Zhang Z
Nanoscale; 2024 May; 16(18):8950-8959. PubMed ID: 38630023
[TBL] [Abstract][Full Text] [Related]
8. Quantification-Promoted Discovery of Glycosylated Exosomal PD-L1 as a Potential Tumor Biomarker.
Zhu L; Xu Y; Kang S; Lin B; Zhang C; You Z; Lin H; Yang C; Song Y
Small Methods; 2022 Sep; 6(9):e2200549. PubMed ID: 35810463
[TBL] [Abstract][Full Text] [Related]
9. Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer.
Niu M; Liu Y; Yi M; Jiao D; Wu K
Front Immunol; 2022; 13():827921. PubMed ID: 35386715
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous detection of cancerous exosomal miRNA-21 and PD-L1 with a sensitive dual-cycling nanoprobe.
Qin X; Xiang Y; Li N; Wei B; Chen Y; Fang D; Fang M; Li Q; Liu J; Tang Y; Li X; Yang F
Biosens Bioelectron; 2022 Nov; 216():114636. PubMed ID: 35986985
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of circulating exosomal PD-L1 and soluble PD-L1 in extranodal NK/T-cell lymphoma, nasal-type.
Li JW; Wei P; Guo Y; Shi D; Yu BH; Su YF; Li XQ; Zhou XY
Am J Cancer Res; 2020; 10(12):4498-4512. PubMed ID: 33415014
[TBL] [Abstract][Full Text] [Related]
12. Homogeneous, Low-volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD-L1 for Cancer Diagnosis and Immunotherapy Response Prediction.
Huang M; Yang J; Wang T; Song J; Xia J; Wu L; Wang W; Wu Q; Zhu Z; Song Y; Yang C
Angew Chem Int Ed Engl; 2020 Mar; 59(12):4800-4805. PubMed ID: 31912940
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1.
Yin Z; Yu M; Ma T; Zhang C; Huang S; Karimzadeh MR; Momtazi-Borojeni AA; Chen S
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472857
[TBL] [Abstract][Full Text] [Related]
14. Ti
Zhou Y; Chen Q; Zhong S; Liu H; Koh K; Chen H
Biosens Bioelectron; 2023 Oct; 237():115493. PubMed ID: 37364303
[TBL] [Abstract][Full Text] [Related]
15. Isolation of circulating exosomes and identification of exosomal PD-L1 for predicting immunotherapy response.
Zhang J; Zhu Y; Guan M; Liu Y; Lv M; Zhang C; Zhang H; Zhang Z
Nanoscale; 2022 Jun; 14(25):8995-9003. PubMed ID: 35700522
[TBL] [Abstract][Full Text] [Related]
16. A magneto-activated nanoscale cytometry platform for molecular profiling of small extracellular vesicles.
Chen K; Duong BTV; Ahmed SU; Dhavarasa P; Wang Z; Labib M; Flynn C; Xu J; Zhang YY; Wang H; Yang X; Das J; Zargartalebi H; Ma Y; Kelley SO
Nat Commun; 2023 Sep; 14(1):5576. PubMed ID: 37696888
[TBL] [Abstract][Full Text] [Related]
17. Multivalence-Actuated DNA Nanomachines Enable Bicolor Exosomal Phenotyping and PD-L1-Guided Therapy Monitoring.
Jin D; Peng XX; Qin Y; Wu P; Lu H; Wang L; Huang J; Li Y; Zhang Y; Zhang GJ; Yang F
Anal Chem; 2020 Jul; 92(14):9877-9886. PubMed ID: 32551501
[TBL] [Abstract][Full Text] [Related]
18. The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target.
Ye L; Zhu Z; Chen X; Zhang H; Huang J; Gu S; Zhao X
Cells; 2021 Nov; 10(11):. PubMed ID: 34831468
[TBL] [Abstract][Full Text] [Related]
19. Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases.
Bailly C; Thuru X; Quesnel B
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34204509
[TBL] [Abstract][Full Text] [Related]
20. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.
Li X; Wang S; Mu W; Barry J; Han A; Carpenter RL; Jiang BH; Peiper SC; Mahoney MG; Aplin AE; Ren H; He J
J Exp Clin Cancer Res; 2022 Jan; 41(1):41. PubMed ID: 35086548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]